Recomlyse Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in Description.
Recomlyse is contraindicated in the following situations because thrombolytic therapy is associated with a higher risk of bleeding: Significant bleeding disorder currently or in the past 6 months; Oral anticoagulant therapy and INR>1.3 (see Bleeding under Precautions); History of central nervous system lesions or trauma (such as intracranial tumors, arteriovenous malformations or aneurysms, intracranial and intraspinal surgeries); Known bleeding constitution; Severe uncontrolled high blood pressure; Have had serious trauma or major surgery within the past 3 months; Recent (within 2 weeks) prolonged cardiopulmonary resuscitation (>2 minutes), obstetrical delivery or non-stress vascular puncture (such as subclavian or jugular vein puncture); Severe liver disease, including hepatic failure, cirrhosis, portal hypertension (esophageal varices), and active hepatitis; Acute pancreatitis, active peptic ulcer, aneurysm, or arterial/venous malformation; Neoplasm with a tendency to bleed; Bacterial endocarditis or pericarditis; Active internal bleeding; Significant or recent severe or dangerous bleeding; Recent (within 2 weeks) prolonged cardiopulmonary resuscitation (>2 minutes), obstetrical delivery, or puncture of non-compressible blood vessel (e.g. subclavian or jugular vein puncture); Aneurysmal subarachnoid haemorrhage or suspected subarachnoid haemorrhage; Patients who are allergic to this product or any excipients.
Supplementary contraindications in the treatment of acute myocardial infarction: History of haemorrhagic stroke or unexplained stroke; History of ischemic stroke or transient ischaemic attack (TIA) within the past 6 months, except ischaemic stroke occurring within 4.5 hours; Confirmed, highly suspected, or unresolved aortic dissection.
Supplementary contraindications when treating acute ischemic stroke: It has been more than 4.5 hours since the onset of ischemic stroke symptoms and intravenous drip treatment has not been started or the time of symptom onset cannot be determined; Mild neurological deficit or rapid improvement of symptoms before starting treatment; Severe stroke assessed clinically (NIHSS>25) and/or imaging examinations; Stroke attacks are accompanied by epileptic seizures; History of stroke within the past 3 months; Acute bleeding tendency, including platelet count below 100 x 10⁹/L or other conditions; Received low molecular weight heparin treatment within 24 hours; Thrombin inhibitors or factor Xa inhibitors were used within 48 hours, and the thromboplastin time was higher than the upper limit of laboratory normal values; History of stroke combined with diabetes; Blood sugar <2.8 mmol/L or >22.22 mmol/L; Head CT or MRI shows large-scale infarction (infarct area >1/3 of the middle cerebral arteryblood supply area); Arterial puncture in a location that is not easy to compress and stop bleeding in the past week; Aortic arch dissection.